CD274 and cancer: Notably, ICIs targeting PD‐1 (programmed cell death protein 1), PD‐L1 (programmed death‐ligand 1), and CTLA‐4 (cytotoxic T‐lymphocyte‐associated protein 4) in conjunction with personalized cancer vaccines has shown promising results.